ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report)’s stock price reached a new 52-week low on Thursday. The stock traded as low as $69.39 and last traded at $69.6420, with a volume of 919,002 shares changing hands. The stock had previously closed at $71.65.
Key Stories Impacting ANI Pharmaceuticals
Here are the key news stories impacting ANI Pharmaceuticals this week:
- Positive Sentiment: ANI reported third-quarter 2026 adjusted earnings of $2.70 per share, above estimates of about $2.18 and up from $2.04 a year earlier. Revenue rose 27.6% year over year to $290.78 million, also topping analyst expectations. ANI Pharmaceuticals third-quarter 2026 results
- Positive Sentiment: ANI proposed acquiring Swedish biotech Egetis Therapeutics for about $560 million. The deal would expand ANI’s rare-disease business and could provide a longer-term growth opportunity if completed and successfully integrated. ANI offer to acquire Egetis Therapeutics
- Negative Sentiment: The acquisition proposal also brings financing, deal-completion and integration risks. Investors may be assessing whether the $560 million purchase price will generate sufficient returns, tempering the positive read-through from the earnings beat.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the company. Canaccord Genuity Group lowered their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price target for the company. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $99.60.
Read Our Latest Report on ANI Pharmaceuticals
ANI Pharmaceuticals Stock Performance
The business’s fifty day simple moving average is $72.74 and its 200-day simple moving average is $77.49. The company has a market capitalization of $1.60 billion, a P/E ratio of 15.01, a P/E/G ratio of 2.33 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.26 million. During the same quarter last year, the firm earned $2.04 EPS. The firm’s revenue for the quarter was up 27.6% compared to the same quarter last year. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Jeanne Thoma sold 1,000 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the sale, the director directly owned 26,762 shares of the company’s stock, valued at approximately $1,914,285.86. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $72.87, for a total transaction of $207,679.50. Following the sale, the chief financial officer owned 166,143 shares of the company’s stock, valued at $12,106,840.41. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,412 shares of company stock valued at $2,220,970 in the last three months. 8.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Illinois Municipal Retirement Fund grew its position in shares of ANI Pharmaceuticals by 7.2% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock worth $706,000 after buying an additional 651 shares in the last quarter. Penn Capital Management Company LLC raised its holdings in shares of ANI Pharmaceuticals by 2.8% in the third quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock valued at $15,515,000 after acquiring an additional 5,884 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of ANI Pharmaceuticals by 4.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 12,695 shares of the specialty pharmaceutical company’s stock valued at $926,000 after acquiring an additional 518 shares in the last quarter. Hohimer Wealth Management LLC raised its holdings in shares of ANI Pharmaceuticals by 4.1% in the third quarter. Hohimer Wealth Management LLC now owns 3,638 shares of the specialty pharmaceutical company’s stock valued at $264,000 after acquiring an additional 142 shares in the last quarter. Finally, Alps Advisors Inc. lifted its stake in ANI Pharmaceuticals by 15.7% in the third quarter. Alps Advisors Inc. now owns 8,242 shares of the specialty pharmaceutical company’s stock worth $599,000 after acquiring an additional 1,117 shares during the period. 76.05% of the stock is owned by institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.
ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
